B+
Bull case
25%
Probability
Target price
$7.25
+111.4% vs current
MNKD
MannKindANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.30
-3.8% vs current
B-
Bear case
30%
Probability
Target price
$2.15
-37.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+64.0
Score
AI commentary
Coverage is thin and the packet is dominated by a primary-source regulatory update rather than a fresh earnings or guidance reset. The stock should react mostly to the May 29 FDA decision, while analyst revision visibility is unavailable here, so confidence stays moderate and the thesis should be monitored rather than chased.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-28catalystFDA removed the Afrezza pulmonary-malignancy PMR overhangMedium impact
The company said the FDA released it from the postmarketing requirement tied to the Afrezza pulmonary-malignancy study, removing one long-running regulatory overhang. [#8-K-2026-05-28]
2026-05-29eventAfrezza pediatric sBLA decision date is imminentHigh impact
The same 8-K says the FDA accepted the supplemental BLA for Afrezza in children and adolescents and set a PDUFA target action date of May 29, 2026, making the near-term setup binary. [#8-K-2026-05-28]
2027-12-31catalystINHALE-1 pediatric study progresses toward late-2027 dataHigh impact
MannKind said INHALE-1 st has added sites, expects enrollment of up to 100 participants across 10 clinical sites, and expects data in late 2027, which gives the pediatric program a longer-dated readout path. [#8-K-2026-05-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology